Search

UT Southwestern biochemist Zhijian “James” Chen, Ph.D., famously identified the cGAS enzyme pathway that alerts the human immune system to disease-causing invaders like viruses. Since then, researchers have found that cGAS signaling is an ancient, conserved defense strategy stretching from bacteria

Led by two UT Southwestern physicians, a team of researchers from 15 U.S. medical centers has performed the first analysis of a potentially game-changing drug to treat upper urinary tract urothelial cancers.

Research teams led by two UT Southwestern Medical Center faculty members have been selected to receive competitive awards from the Howard Hughes Medical Institute’s (HHMI) Emerging Pathogens Initiative (EPI).

UT Southwestern researchers have discovered a new form of progeria, a rare premature-aging syndrome, in a man from Malaysia and traced its cause to a novel gene mutation.

Using the CRISPR-Cas9 gene editing system, UT Southwestern researchers corrected mutations responsible for a common inherited heart condition called dilated cardiomyopathy (DCM) in human cells and a mouse model of the disease.

UT Southwestern researchers have identified the molecular function of 87 inherited genetic variants that affect the risk of prostate cancer, and the majority appear to control the activity of genes located far away from the risk variants themselves.

Antibodies that target specific tuberculosis (TB) proteins are effective at inhibiting the bacteria that cause TB, the infectious disease that claims the most lives worldwide, a study led by UT Southwestern Medical Center researchers found.

A single, high dose of radiation delivered before other treatments could completely eradicate tumors in most women with early-stage, operable hormone-positive breast cancer, according to a study led by UT Southwestern Medical Center researchers.

More than two-thirds of 16-year-olds today have been through a traumatic event, such as the Central Texas flooding in July that killed over 130 people, including numerous children at summer camp.

Immunotherapy drugs that target a protein called programmed death ligand 1 (PD-L1) on the surface of cancer cells have quickly become a mainstay to treat many forms of cancer, often with dramatic results.